Beyond the Car: Toyota and MaRS Fuel the Future of Human Agility

TORONTO, ON – November 12, 2026 — For over a century, the concept of mobility has been inextricably linked to the internal combustion engine and the open road. Today, that definition is undergoing a radical, human-centric transformation. The frontier of movement is no longer just about traversing highways; it is about navigating the living room, the workplace, and the complex terrain of the human body itself.

This paradigm shift was squarely in focus this week as the Toyota Mobility Foundation (TMF), in partnership with the MaRS Discovery District, unveiled the ten international startups selected for the third cohort of the Mobility Unlimited Hub (MUH). Supported by a coalition of health innovation heavyweights—including the Centre for Aging + Brain Health Innovation (CABHI), the Ontario Brain Institute (OBI), and OBIO—the two-year program is designed to accelerate the commercialization of technologies that address active mobility and cognitive health.

Yet, beyond the standard accelerator fanfare lies a much larger narrative. This initiative highlights a critical intersection where venture capital, highly regulated health technology, and the strategic repositioning of one of the world's largest automakers collide.

Commercializing Accessibility: Toronto as a Global Testbed

Historically, the development of assistive technologies has been relegated to the realm of philanthropy or niche medical research. The Mobility Unlimited Hub is actively dismantling that assumption, proving that accessibility tech is a robust, viable venture sector.

Results from the Hub's first two cohorts provide a compelling proof of concept. In the past year alone, participating ventures have raised more than $22 million in private and public funding, and they are currently on track to generate a combined revenue of $33 million. This financial velocity demonstrates that early-stage innovation in the assistive space can scale rapidly when backed by the right formula of strategic marketing, investor access, and regulatory navigation.

"We at MaRS are thrilled to welcome the members of the Mobility Unlimited Hub's third cohort. Drawing on the strength of the ecosystem, the founders in this program will continue to develop and refine technologies aimed at helping people around the world smash barriers, gain independence and enjoy active mobility," says Grace Lee Reynolds, CEO of MaRS Discovery District. "We will provide them with the tools, expertise and guidance they need to scale up their technologies so they can make an even greater impact on the lives of people around the world."

The 2026–2028 cohort features a diverse array of hardware and software solutions that read like science fiction made manifest. Niagara Falls–based Better Bionics is developing a neuroprosthetic hand with human-level dexterity. Ottawa's Sielo Robotics has engineered an affordable wheelchair-mounted robotic arm for individuals with spinal cord injuries. Meanwhile, U.S.-based XRAI is deploying multimodal AI captioning and real-time translation software across smart glasses in over 300 languages for deaf and hard-of-hearing users.

These are not merely incremental improvements to existing devices; they are fundamental reimaginations of the human-machine interface. However, bringing these technologies from the laboratory to the living room requires navigating a labyrinth of regulatory and economic barriers.

Closing the 20 Percent Deficit: Where Innovation Meets Policy

The demand for these innovations is undeniable. According to recent data from Statistics Canada, nearly a quarter of Canadians are living with one or more disabilities. More alarmingly, over 20 percent of those individuals report that their requirements for aids or assistive devices remain unmet.

This glaring deficit is rarely a result of a lack of technological capability, but rather a collision between cutting-edge innovation and archaic reimbursement policies. Canada's fragmented, provincially administered healthcare system often struggles to categorize and fund novel devices. Programs like Ontario's Assistive Devices Program (ADP) are designed to cover the costs of "basic" and "essential" equipment. When a startup introduces a device powered by artificial intelligence or continuous biometric feedback, it often falls outside the rigid definitions of legacy funding models, leaving the end-user with prohibitive out-of-pocket costs.

Furthermore, the regulatory pathways for these startups are notoriously steep. Companies in the new cohort, such as Halifax-based Emagix—which uses precision disease monitoring software to detect blinding retinal diseases—and Kitchener-based HeadFirst, face rigorous scrutiny. HeadFirst is developing rapid, saliva-based diagnostic tests for concussion biomarkers. As an in vitro diagnostic device, this technology will likely require stringent Class III or IV licensing from Health Canada and equivalent clearances from the U.S. FDA before it can reach consumers.

"We're excited to join the Mobility Unlimited Hub and learn from our fellow cohort members and the broader network of experts and partners at MaRS and the Toyota Mobility Foundation," says Andrew Cordssen-David, CEO of HeadFirst. "For us, the timing is especially valuable because we're at a transition point, building on our R&D and moving toward commercialization. Having access to the resources and expertise of the Toyota Mobility Foundation and MaRS will help us take that next step and scale up."

The Hub's true value proposition lies in its ability to guide founders through this "valley of death"—the perilous gap between R&D and commercial viability. By providing access to regulatory experts and health innovation bodies like OBI and CABHI, the program helps startups build the clinical evidence required not just for regulatory approval, but for eventual integration into public and private insurance frameworks.

Innovations like Vessl Prosthetics' battery-free, automatic volume-management system for lower limbs, or PROVA Innovations' smart-insole biofeedback platform, have the potential to drastically reduce long-term healthcare costs by accelerating rehabilitation and preventing secondary complications. The challenge is convincing policymakers to invest in the upfront hardware.

Beyond the Automobile: Inside Toyota's Long-Term Play

While the immediate impact of the MUH is felt by the startups and the populations they serve, the initiative also offers a fascinating glimpse into the corporate strategy of its primary backer. The Toyota Mobility Foundation is not merely a philanthropic side project; it is a core component of Toyota Motor Corporation's existential pivot.

Faced with a future of autonomous driving, shifting urban infrastructure, and an aging global population, Toyota is actively transitioning from a traditional automaker into a universal "mobility company." This strategy relies on the premise that the future of transportation will be multimodal, deeply personalized, and highly integrated into daily life.

"The Toyota Mobility Foundation is not standing still; we work with MaRS to continually improve the hub and our understanding of what constitutes and enables active mobility and the active independence and agency it provides," says William Chernicoff, program manager at Toyota Mobility Foundation. "The additional support of CABHI, OBI and OBIO validates our vision around creating, anchoring and scaling an ecosystem that will bring in new and impactful collaborators and deliver more solutions to more people more quickly."

Toyota's expanding patent portfolio reflects this shift, with heavy investments in service robotics, personal mobility devices like the C+walk series, and smart city infrastructure via projects like Japan's Woven City. By funding early-stage ventures in neuroprosthetics, self-balancing wheelchairs (like cohort member Genny Factory SA), and AI diagnostics, Toyota is effectively outsourcing specialized R&D.

The insights gleaned from how a neuroprosthetic interfaces with the human nervous system, or how AI can predict movement intent, are highly transferable. Today, these technologies help a stroke survivor regain hand function via Sudbury-based IRegained; tomorrow, those same underlying algorithms could inform the human-machine interfaces of Toyota's next generation of autonomous vehicles or in-home support robots.

"TMF aims to create a truly mobile society that will help people live better lives no matter where they are," says Akio Toyoda, chair of TMF.

Ultimately, the Mobility Unlimited Hub represents a crucial testing ground for the future of human agility. As the startups in this third cohort begin their two-year journey toward commercialization, they are not just building products; they are building the infrastructure for a society that refuses to let physical or cognitive limitations dictate the boundaries of human experience.